The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hello JT
Good points. The following may help with some answers:
Alistair stated during the on-line video presentation that:
“We are seeing therapeutically significant levels of Dox in the tumour biopsies”. To repeat, as Alistair did, “THERAPUTICALLY SIGNIFICNT LEVELS”.
Alistair goes on to say, “we know the levels of doxorubicin required to make the drug work and the levels we are seeing in the biopsies are greater. That’s what we can say factually now”. Alistair goes on to say, “Why the H*ll wouldn’t it work”?
Watch the AGM video from 1:04:25 – 1:08:50 https://www.youtube.com/watch?v=DlHRRmycxTY
Covid or Cancer
Covid is new and has been with us for 3 to 4 years. The world knows about Covid and some will have lost friends or loved ones to this recent disease.
The world also knows about Cancer. Cancer has been with us for centuries and most, if not all, will have lost a friend or loved one to this terrible disease. We tend to live with the impact of Cancer in our lives.
Doxorubicin has been with us for over 50 years and, like so many other medical toxins, Dox’ brings many negatives as well as positives.
pre|CISION™ brings something revolutionary. To quote Alastair Smith, “pre|CISION™ will bring a paradigm shift in how chemotherapy will be delivered to cancer patients”.
We are at a turning point in global Cancer care. We will all be eagerly watching the scientific updates over the coming weeks and months. We are reaching that “paradigm shift”.
I have been invested with Avacta for over 10 years. There are always investment risks on AIM, however, LTH’s supporting Avacta are about to deliver the “paradigm shift”.
Good luck to all who require treatment(s) and to those who have invested and supported Avacta.
Lots more to come in Q4, 2023.
GLA, stay safe and well, …
Remember, the pre|CISION platform is not a test, it is an opportunity for multiple treatments without side effects.
A positive share price rise this week but it will go much higher in the near future, (IMHO).
The follow comments are direct from Dr Alastair Smith, Chief Executive of Avacta Group plc:
19th September 2023
“I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.
The safety and initial efficacy signals emerging from the data in the AVA6000 Phase 1 study are very encouraging indeed. The pre|CISIONTM platform is doing exactly what it was designed to do – target the release of active chemotherapy to the tumour tissue, sparing healthy tissues and improving the safety and tolerability of the drug whilst delivering potentially superior efficacy.
I’m particularly pleased that, even at this early stage and in this patient group, we have a confirmed, significant response in a patient with soft tissue sarcoma, as well as other positive signals across a number of other patients.
We’re now aiming to accelerate the clinical development of AVA6000 and begin the Phase 2 efficacy study earlier than originally planned. The Phase 2 trial will follow a short study to determine the safety and efficacy of fortnightly dosing to allow us to determine the recommended Phase 2 dosing regimen.
I look forward very much to sharing the detailed data from the Phase 1a study in due course.”
https://avacta.com/successful-completion-of-als-6000-101-sixth-dose-escalation-and-clinical-update/
Not long now until Big Pharma form an orderly queue outside the Avacta conference room.
Current share price does not reflect the science or opportunity.
GLA
During the Covid pandemic, the markets believed that Avacta had a market leading diagnostic test and the share price soared to £ 2.85. That share price was for a Test, not a Treatment / Cure.
Avacta’s pre|CISION™ is a PLATFORM with two pre|CISION™ products (AVA6000 & AVA3996) currently coming through clinical trials.
Avacta’s pre|CISION™ products are not a tests, they are treatments. They are possible cures for Cancer and other illnesses. Avacta’s pre|CISION™ platform offers multiple opportunities for other lifesaving products and licencing/partnering agreements.
If a Covid test was worth £ 2.85 per share, a life saving platform (pre|CISION™) is worth considerably more.
Share price moving up and more ground breaking news to come during Q4, 2023.
Another positive share price day?
GLA
It is 12 months (05 Sep 2022) since AVA6000 received Orphan Drug Designation from the US Food and Drug Administration
https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/
It is 6 months (06 Apr 2023) since Avacta Opened First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
https://avacta.com/avacta-opens-first-two-us-clinical-investigator-sites-for-ava6000-phase-1-clinical-study/
It is 6 days (19 Sep 2023) since the Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
https://avacta.com/successful-completion-of-als-6000-101-sixth-dose-escalation-and-clinical-update/
4 days (28 Sep 202) until interim results for the six months ended 30 June 2023
https://avacta.com/notice-of-results-2/
Q4 (Oct to Dec) is going to be very interesting.
GLA
Https://en.wikipedia.org/wiki/Tom_Winnifrith
Winnifrith was expelled from the Liberal Democrat Party by Paddy Ashdown in 1993 for allegedly "pandering to racism". He was subject to an investigation by Metropolitan Police Service at the request of the Attorney General at the time, Sir Nicholas Lyell, and then Shadow Cabinet Minister Jack Straw, which found no wrongdoing.
In September 2017, Winnifrith authored an article that claimed that the FCA would not be shutting down Beaufort Securities. In March 2018, Beaufort Securities was shut down, declared insolvent, and charged with fraud, following a joint FCA, FBI, SEC and DOJ investigation.
His time as CEO of Rivington Street Holdings (RSH) has also come under criticism, including accusations of multiple compliance failures while running a regulated company and acting "ultra vires", attempting to sell an FSA regulated entity without the approval of the RSH board.
Make up your own mind. Expecting RNS(s) this month.
21st June 2023: RNS announcing successful completion of Cohort V. https://avacta.com/successful-completion-of-fifth-dose-escalation-in-ava6000-phase-1-clinical-study/
28th June 2023: Avacta AGM with many positive takeaways. https://avacta.com/annual-general-meeting-and-shareholder-event/
June / July 2023: Cohort VI begins.
19th September 2023: Shaun Chilton completes 3 months with Avacta as Non-executive Director, https://avacta.com/director-appointment-2/
19th September 2023: Target start date for Chief Business Officer.
28th September 2023: We will have Avacta’s unaudited interim results for the six months ended 30 June 2023, https://avacta.com/notice-of-results-2/
Almost 3 months since 21st June and the last, Science related, RNS.
Expecting very positive SCIENTIFIC news and the next steps during September 2023.
GLA
With pre|CISION™, AVA6000, AVA3996 and many others, general consensus is that Avacta is seriously undervalued at this time. Could Avacta also be a target for Private Equity? Will Big Pharma step in soon to avoid having to pay a considerable multiplier in 12 to 18 months?
Who knows for sure?
GLA
Private Equity swoops on UK pharma firm in £703.1m deal:
Ergomed founder lands £120m windfall
https://www.thisismoney.co.uk/money/markets/article-12480007/Private-equity-swoops-UK-pharma-firm-703-1m-deal-Ergomed-founder-lands-120m-windfall.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_gl=1*1ti4d9v*_ga*MTc3NjA5ODgzNC4xNjkzOTAzNjc0*_ga_XE0XLFFF16*MTY5MzkwMzY3My4xLjEuMTY5MzkwMzcwMC4wLjAuMA..
Avacta current market cap
Private Equity swoops on UK pharma firm in £703.1m deal: Ergomed founder lands £120m windfall
https://www.thisismoney.co.uk/money/markets/article-12480007/Private-equity-swoops-UK-pharma-firm-703-1m-deal-Ergomed-founder-lands-120m-windfall.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_gl=1*1ti4d9v*_ga*MTc3NjA5ODgzNC4xNjkzOTAzNjc0*_ga_XE0XLFFF16*MTY5MzkwMzY3My4xLjEuMTY5MzkwMzcwMC4wLjAuMA..
Avacta current market cap
That would make sense. So possible additional funding from China?
Always a good idea to have company websites in several languages. The interesting thing is that the second language is Chinese rather than Spanish, Arabic or another Asian language. Possibility of investment from China?
Not if they have not finished C6 yet. There could be signs of MTD with C6 continuing while Avacta draws conclusions and prepares a plan.
RNS stating we have found MTD or an RNS with MTD and Phase1b strategy. Know which one I would prefer.